Bio-Techne Corporation (TECH)
| Market Cap | 11.06B |
| Revenue (ttm) | 1.21B |
| Net Income (ttm) | 109.50M |
| Shares Out | 155.83M |
| EPS (ttm) | 0.69 |
| PE Ratio | 102.20 |
| Forward PE | 35.44 |
| Dividend | $0.32 (0.45%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | 12,259,237 |
| Open | 70.85 |
| Previous Close | 70.70 |
| Day's Range | 70.67 - 71.23 |
| 52-Week Range | 43.20 - 72.16 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 67.69 (-4.66%) |
| Earnings Date | Aug 5, 2026 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur... [Read more]
Financial Performance
In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $67.69, which is a decrease of -4.66% from the latest price.
News
Bio-Techne downgraded to Neutral from Buy at Citi
Citi downgraded Bio-Techne (TECH) to Neutral from Buy with a $73 price target after the company agreed to be acquired for $73 per share by Merck KGaA (MKGAY). Published first…
Bio-Techne downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Steven Etoch downgraded Bio-Techne (TECH) to Equal Weight from Overweight with a price target of $73, up from $68, after the company agreed to be acquired for $73…
Bio-Techne price target raised to $73 from $49 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Bio-Techne (TECH) to $73 from $49 and keeps a Neutral rating on the shares. The firm raised its target…
Bio-Techne downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Bio-Techne (TECH) to Hold from Buy with a price target of $73, up from $66, following Merck KGaA’s proposed acquisition at $73 per share. Published first on…
Bio-Techne downgraded to Market Perform from Outperform at William Blair
William Blair analyst Matt Larew downgraded Bio-Techne (TECH) to Market Perform from Outperform and removed shares from the firm’s Conviction List after the company agreed to be acquired for $73…
Bio-Techne downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Bio-Techne (TECH) to Market Perform from Outperform with a $73 price target after Merck KGaA (MKGAF) agreed to acquire Bio-Techne for $73 per share in cash. Published first…
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Merck KGaA to acquire Bio-Techne for $73 per share in cash
Merck KGaA (MKGAF) and Bio-Techne (TECH) entered into a definitive agreement pursuant to which Merck KGaA will, subject to customary closing conditions, acquire Bio-Techne for $73 per share in cash,…
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre m...
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Bio-Techne named a best smid-cap idea at TD Cowen
TD Cowen analyst Kyle Boucher names Bio-Techne (TECH) a best smid-cap idea in 2026 while keeping a Buy rating on the shares with a $65 price target TD views the…
Bio-Techne initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Bio-Techne (TECH) with a Neutral rating and $65 price target The firm launched coverage of the life science tools sector with a “feet in the…
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within icIEF-resolved charge variants Four-hour workflow reduces develo...
Bio-Techne resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Bio-Techne (TECH) with an Outperform rating and $62 price target Bio-Techne is the most levered company to the improved biotech funding environment in the firm’s…
Bio-Techne Transcript: Bank of America Global Healthcare Conference 2026
Q3 saw -2% growth due to order timing and weak early-stage biotech, but core products and growth verticals outperformed. Large pharma and China showed strong, broad-based growth, while academic markets stabilized. AI and automation trends are boosting demand for high-quality data.
Bio-Techne price target lowered to $66 from $75 at Deutsche Bank
Deutsche Bank analyst Justin Bowers lowered the firm’s price target on Bio-Techne (TECH) to $66 from $75 and keeps a Buy rating on the shares.
Bio-Techne price target lowered to $49 from $70 at Baird
Baird lowered the firm’s price target on Bio-Techne (TECH) to $49 from $70 and keeps a Neutral rating on the shares. The firm updated its model following Q3 organic growth…
Bio-Techne price target lowered to $50 from $65 at Stifel
Stifel lowered the firm’s price target on Bio-Techne (TECH) to $50 from $65 and keeps a Hold rating on the shares.
Bio-Techne price target lowered to $50 from $54 at Evercore ISI
Evercore ISI analyst Daniel Markowitz lowered the firm’s price target on Bio-Techne (TECH) to $50 from $54 and keeps an In Line rating on the shares.
Bio-Techne price target lowered to $70 from $80 at Citi
Citi lowered the firm’s price target on Bio-Techne (TECH) to $70 from $80 and keeps a Buy rating on the shares. The firm reduced the company’s estimates post the fiscal…
Bio-Techne Earnings Call Transcript: Q3 2026
Q3 saw a 2% organic revenue decline, but underlying growth was 2% excluding timing impacts. Large pharma and China remained strong, while biotech softness persisted. Margin expansion and robust growth in spatial biology and GMP proteins position the company for acceleration in FY2027.